Status:
COMPLETED
A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
A study to compare rofecoxib versus naproxen in the treatment of Chinese patients with rheumatoid arthritis.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Chinese males or females at least 18 years of age with rheumatoid arthritis
Exclusion
Key Trial Info
Start Date :
January 7 2004
Trial Type :
INTERVENTIONAL
End Date :
September 19 2004
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00157872
Start Date
January 7 2004
End Date
September 19 2004
Last Update
May 25 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.